ICICI Direct's research report on Suven Pharmaceuticals
Suven Pharma is a CDMO that supports global life sciences industry & fine chemical majors in their NCE development endeavours. Its services include custom synthesis, process R&D, scale-up & contract manufacturing. Business comprises three segments – CDMO (development projects and commercial supplies), specialty chemicals and contract technical service CDMO vertical contributes more than 62% of its topline. Owing to its CDMO competence, it has developed & supplies intermediates for two specialty chemical products (agrochemical) to large global conglomerates
Outlook
We retain our BUY rating on this stock We value Suven at Rs 650 with 32x P/E on FY23E EPS
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
Read More
